Vnitr Lek 2016, 62(6):431-432

Roční sledování vedlejších účinků podávání sitagliptinu u pacientů s diabetem 2. typu - editorial

Alena Adamíková
Diabetologické centrum Interní kliniky Krajské nemocnice T. Bati, a.s., Zlín

Received: February 24, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamíková A. Roční sledování vedlejších účinků podávání sitagliptinu u pacientů s diabetem 2. typu - editorial. Vnitr Lek. 2016;62(6):431-432.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scirica BM, Bhatt DL, Braunwald E et al. [SAVOR-TIMI 53 Steering Committee and Investigators]. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-1326. Go to original source... Go to PubMed...
    2. Zannad F, Cannon CP, Cushman WC et al. [EXAMINE Investigators]. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385(9982): 2067-2076. Go to original source... Go to PubMed...
    3. Green JB, Bethel MA, Armstrong PW et al. [TECOS Study Group]. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232-242. Erratum in Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. [N Engl J Med 2015] Go to original source... Go to PubMed...
    4. Sanyal AJ. [American Gastroenterological Association]. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123(5): 1705-1725. Go to original source... Go to PubMed...
    5. Choudhury J, Sanyal AR. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24(4): 349-362. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.